Peters anomaly

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:708OMIM:604229Q13.4
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Peters anomaly is a rare congenital eye disorder classified as an anterior segment dysgenesis. It is characterized by a central corneal opacity (leukoma) present at birth, along with defects in the posterior layers of the cornea (Descemet membrane and endothelium) and adhesions (synechiae) between the iris and the cornea. The condition primarily affects the anterior segment of the eye and can lead to significant visual impairment or blindness if untreated. Peters anomaly is typically divided into two types: Type I involves central corneal opacity with iridocorneal adhesions but without lens involvement, while Type II includes corneolenticular adhesions or contact, often with cataracts and more severe visual compromise. The condition may be unilateral or bilateral, with bilateral cases tending to be more severe. Peters anomaly can occur as an isolated ocular finding or as part of a broader syndrome known as Peters plus syndrome, which includes short stature, brachydactyly, developmental delay, and characteristic facial features. Isolated Peters anomaly has been associated with mutations in several genes involved in anterior segment development, including PAX6, PITX2, PITX3, FOXC1, FOXE3, and CYP1B1. Peters plus syndrome is caused by mutations in the B3GLCT gene. Glaucoma is a frequent and serious complication, occurring in approximately 50-70% of affected individuals, and can be difficult to manage. Treatment of Peters anomaly is challenging and often requires a multidisciplinary approach. Corneal transplantation (penetrating keratoplasty) may be performed to restore corneal clarity, though graft survival rates in infants and young children are lower than in adults due to a higher risk of rejection and other complications. Management of associated glaucoma may involve medical therapy, surgical procedures such as goniotomy, trabeculotomy, or glaucoma drainage devices. Early intervention is critical to prevent amblyopia, and affected children typically require long-term ophthalmologic follow-up. Optical rehabilitation, including contact lenses and visual aids, may also be necessary to optimize visual outcomes.

Also known as:

Clinical phenotype terms— hover any for plain English:

Peters anomalyHP:0000659Subcapsular cataractHP:0000523Opacification of the corneal stromaHP:0007759Anterior synechiae of the anterior chamberHP:0011483Central opacification of the corneaHP:0011493Thinning of Descemet membraneHP:0031159Developmental glaucomaHP:0001087
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Peters anomaly.

View clinical trials →

No actively recruiting trials found for Peters anomaly at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Peters anomaly community →

Specialists

1 foundView all specialists →
ND
Nicolas NC CHASSAING, Dr
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Peters anomaly.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Peters anomalyForum →

No community posts yet. Be the first to share your experience with Peters anomaly.

Start the conversation →

Latest news about Peters anomaly

No recent news articles for Peters anomaly.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Peters anomaly

What is Peters anomaly?

Peters anomaly is a rare congenital eye disorder classified as an anterior segment dysgenesis. It is characterized by a central corneal opacity (leukoma) present at birth, along with defects in the posterior layers of the cornea (Descemet membrane and endothelium) and adhesions (synechiae) between the iris and the cornea. The condition primarily affects the anterior segment of the eye and can lead to significant visual impairment or blindness if untreated. Peters anomaly is typically divided into two types: Type I involves central corneal opacity with iridocorneal adhesions but without lens in

At what age does Peters anomaly typically begin?

Typical onset of Peters anomaly is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Peters anomaly?

1 specialists and care centers treating Peters anomaly are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.